Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.01
BMRN's Cash to Debt is ranked higher than
57% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. BMRN: 1.01 )
BMRN' s 10-Year Cash to Debt Range
Min: 0.12   Max: No Debt
Current: 1.01

Equity to Asset 0.62
BMRN's Equity to Asset is ranked higher than
70% of the 970 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. BMRN: 0.62 )
BMRN' s 10-Year Equity to Asset Range
Min: -0.66   Max: 0.97
Current: 0.62

-0.66
0.97
F-Score: 5
Z-Score: 10.31
M-Score: -3.00
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -12.37
BMRN's Operating margin (%) is ranked higher than
80% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -71.67 vs. BMRN: -12.37 )
BMRN' s 10-Year Operating margin (%) Range
Min: -1075   Max: 13.41
Current: -12.37

-1075
13.41
Net-margin (%) -17.84
BMRN's Net-margin (%) is ranked higher than
79% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. BMRN: -17.84 )
BMRN' s 10-Year Net-margin (%) Range
Min: -1025   Max: 54.7
Current: -17.84

-1025
54.7
ROE (%) -9.18
BMRN's ROE (%) is ranked higher than
81% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. BMRN: -9.18 )
BMRN' s 10-Year ROE (%) Range
Min: -751.65   Max: 39.6
Current: -9.18

-751.65
39.6
ROA (%) -5.64
BMRN's ROA (%) is ranked higher than
83% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. BMRN: -5.64 )
BMRN' s 10-Year ROA (%) Range
Min: -76.62   Max: 18.88
Current: -5.64

-76.62
18.88
ROC (Joel Greenblatt) (%) -14.18
BMRN's ROC (Joel Greenblatt) (%) is ranked higher than
84% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. BMRN: -14.18 )
BMRN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -433   Max: 24.82
Current: -14.18

-433
24.82
Revenue Growth (3Y)(%) 10.00
BMRN's Revenue Growth (3Y)(%) is ranked higher than
84% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: -0.50 vs. BMRN: 10.00 )
BMRN' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 97.7
Current: 10

0
97.7
» BMRN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

BMRN Guru Trades in Q1 2014

John Burbank 5,173 sh (New)
Manning & Napier Advisors, Inc 171,510 sh (New)
Ray Dalio 48,400 sh (New)
PRIMECAP Management 8,163,719 sh (+7.98%)
John Griffin 2,060,000 sh (unchged)
Jim Simons Sold Out
Frank Sands 9,737,665 sh (-4.87%)
Columbia Wanger 1,389,000 sh (-32.08%)
Steven Cohen 62,853 sh (-82.46%)
» More
Q2 2014

BMRN Guru Trades in Q2 2014

Manning & Napier Advisors, Inc 244,060 sh (+42.3%)
Frank Sands 11,925,248 sh (+22.47%)
John Griffin 2,100,000 sh (+1.94%)
Steven Cohen 90,100 sh (unchged)
John Burbank Sold Out
Ray Dalio Sold Out
PRIMECAP Management 8,064,219 sh (-1.22%)
Columbia Wanger 1,167,800 sh (-15.93%)
» More
Q3 2014

BMRN Guru Trades in Q3 2014

Joel Greenblatt 3,885 sh (New)
Paul Tudor Jones 5,913 sh (New)
Steven Cohen 675,600 sh (+649.83%)
Manning & Napier Advisors, Inc 288,180 sh (+18.08%)
John Griffin 2,230,000 sh (+6.19%)
Frank Sands 12,098,628 sh (+1.45%)
PRIMECAP Management 8,043,918 sh (-0.25%)
Columbia Wanger 853,800 sh (-26.89%)
» More
Q4 2014

BMRN Guru Trades in Q4 2014

Louis Moore Bacon 56,100 sh (New)
RS Investment Management 94,400 sh (New)
Frank Sands 12,183,113 sh (+0.7%)
Manning & Napier Advisors, Inc 288,180 sh (unchged)
John Griffin 2,230,000 sh (unchged)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
PRIMECAP Management 8,016,518 sh (-0.34%)
Columbia Wanger 416,200 sh (-51.25%)
Steven Cohen 74,600 sh (-88.96%)
» More
» Details

Insider Trades

Latest Guru Trades with BMRN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-12-31 Sold Out $67.27 - $94.19 $ 107.0728%0
John Griffin 2014-09-30 Add 6.19%0.11%$55.78 - $73 $ 107.0763%2230000
Joel Greenblatt 2014-09-30 New Buy$55.78 - $73 $ 107.0763%3885
Frank Sands 2014-06-30 Add 22.47%0.35%$56.15 - $68.61 $ 107.0777%11925248
Ray Dalio 2014-06-30 Sold Out 0.03%$56.15 - $68.61 $ 107.0777%0
John Burbank 2014-06-30 Sold Out 0.01%$56.15 - $68.61 $ 107.0777%0
Ray Dalio 2014-03-31 New Buy0.03%$64.99 - $83.28 $ 107.0745%48400
John Burbank 2014-03-31 New Buy0.01%$64.99 - $83.28 $ 107.0745%5173
John Griffin 2013-12-31 Add 17.71%0.23%$59.3 - $75.09 $ 107.0758%2060000
Frank Sands 2013-09-30 Reduce -9.49%0.2%$58.64 - $78.388 $ 107.0761%10268812
Meridian Funds 2013-06-30 Sold Out 0.09%$54.72 - $70.3 $ 107.0772%0
Frank Sands 2013-03-31 Add 10.9%0.24%$49.2 - $62.39 $ 107.0790%10951298
Meridian Funds 2013-03-31 Reduce -69.03%0.17%$49.2 - $62.39 $ 107.0790%40700
Frank Sands 2012-12-31 Add 450.74%1.56%$36.78 - $50.17 $ 107.07135%9874728
Daniel Loeb 2012-12-31 Sold Out 0.79%$36.78 - $50.17 $ 107.07135%0
Meridian Funds 2012-12-31 Reduce -60.99%0.3%$36.78 - $50.17 $ 107.07135%131400
John Griffin 2012-12-31 Reduce -20.09%0.28%$36.78 - $50.17 $ 107.07135%1750000
John Griffin 2012-09-30 New Buy1.4%$37.23 - $43.29 $ 107.07172%2190000
Daniel Loeb 2012-09-30 New Buy0.79%$37.23 - $43.29 $ 107.07172%1000000
George Soros 2012-06-30 Sold Out 0.15%$32.53 - $38.87 $ 107.07197%0
Andreas Halvorsen 2012-06-30 Sold Out 0.12%$32.53 - $38.87 $ 107.07197%0
Richard Perry 2012-06-30 Sold Out 0.04%$32.53 - $38.87 $ 107.07197%0
Andreas Halvorsen 2012-03-31 New Buy0.12%$33.68 - $38.34 $ 107.07225%431923
George Soros 2012-03-31 Add 300%0.11%$33.68 - $38.34 $ 107.07225%300000
Richard Perry 2012-03-31 New Buy0.04%$33.68 - $38.34 $ 107.07225%22900
George Soros 2011-12-31 Reduce -57.14%0.05%$30.07 - $35.38 $ 107.07226%75000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 10.33
BMRN's P/B is ranked higher than
65% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. BMRN: 10.33 )
BMRN' s 10-Year P/B Range
Min: 3.68   Max: 28.5
Current: 10.33

3.68
28.5
P/S 23.79
BMRN's P/S is ranked higher than
75% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 29.06 vs. BMRN: 23.79 )
BMRN' s 10-Year P/S Range
Min: 3.37   Max: 94.86
Current: 23.79

3.37
94.86
EV-to-EBIT -182.54
BMRN's EV-to-EBIT is ranked higher than
56% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BMRN: -182.54 )
BMRN' s 10-Year EV-to-EBIT Range
Min: -1611.4   Max: 67133.8
Current: -182.54

-1611.4
67133.8
Current Ratio 5.22
BMRN's Current Ratio is ranked higher than
76% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. BMRN: 5.22 )
BMRN' s 10-Year Current Ratio Range
Min: 0.9   Max: 18.94
Current: 5.22

0.9
18.94
Quick Ratio 4.23
BMRN's Quick Ratio is ranked higher than
73% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. BMRN: 4.23 )
BMRN' s 10-Year Quick Ratio Range
Min: 0.82   Max: 18.77
Current: 4.23

0.82
18.77
Days Inventory 527.06
BMRN's Days Inventory is ranked higher than
76% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BMRN: 527.06 )
BMRN' s 10-Year Days Inventory Range
Min: 106.92   Max: 917.29
Current: 527.06

106.92
917.29
Days Sales Outstanding 70.21
BMRN's Days Sales Outstanding is ranked higher than
80% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 114.29 vs. BMRN: 70.21 )
BMRN' s 10-Year Days Sales Outstanding Range
Min: 50.96   Max: 212.92
Current: 70.21

50.96
212.92

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 11.99
BMRN's Price/Tangible Book is ranked higher than
70% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 9.29 vs. BMRN: 11.99 )
BMRN' s 10-Year Price/Tangible Book Range
Min: 2.15   Max: 103.23
Current: 11.99

2.15
103.23
Price/DCF (Projected) 38.52
BMRN's Price/DCF (Projected) is ranked higher than
91% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BMRN: 38.52 )
BMRN' s 10-Year Price/DCF (Projected) Range
Min: 19.77   Max: 234.29
Current: 38.52

19.77
234.29
Price/Median PS Value 1.53
BMRN's Price/Median PS Value is ranked higher than
79% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 2.46 vs. BMRN: 1.53 )
BMRN' s 10-Year Price/Median PS Value Range
Min: 0.26   Max: 9.92
Current: 1.53

0.26
9.92
Earnings Yield (Greenblatt) -0.50
BMRN's Earnings Yield (Greenblatt) is ranked higher than
85% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. BMRN: -0.50 )
BMRN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 3.3
Current: -0.5

0.3
3.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BM8.Germany,
Biomarin Pharmaceutical Inc was incorporated in Delaware on October 1996 and began operations on March 21, 1997. It develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent an unmet medical need. Its product portfolio is comprised of five approved products and multiple investigational product candidates. Approved products include VIMIZIM (elosulfase alfa), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). The Company is conducting clinical trials on several investigational product candidates for the treatment of various diseases including PEG PAL, an enzyme substitution therapy for the treatment of PKU; BMN 701, an enzyme replacement therapy for Pompe disease, a glycogen storage disorder; BMN 673, an orally available poly-ADP ribose polymerase inhibitor for the treatment of patients with certain cancers BMN 111, a peptide therapeutic for the treatment of achondroplasia, the cause of dwarfism: and BMN 190 for the treatment of late infantile neuronal ceroid lipofuscinosis(CLN2), lysomal storage disorder affecting the brain. The Company faces competition from biological products approved through an abbreviated regulatory pathway. The Company operates in a regulated industry, which is subject to significant federal, state, local and foreign regulation.
» More Articles for BMRN

Headlines

Articles On GuruFocus.com
You Can No Longer Ignore Biotech Feb 07 2014 
Weekly Top Insider Sells: AAPL, GILD, BMRN, and PCLN Nov 19 2012 
WEEKLY CFO SELLS HIGHLIGHT: VVUS, DIS, SNPS, TXRH, BMRN Mar 04 2012 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
Weekly CFO Sells Highlight: MSCC, BMRN, VAL, CUTR, REX, CIEN Oct 02 2011 
BioMarin Pharmaceutical Inc. Reports Operating Results (10-K) Feb 24 2011 
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,000 Shares Dec 13 2010 
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 2,000 Shares Dec 13 2010 
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,000 Shares Dec 07 2010 
BioMarin Pharmaceutical Inc. (BMRN) SVP, CFO Jeffrey H Cooper sells 11,250 Shares Nov 24 2010 

More From Our Partners
Company News for February 27, 2015 - Corporate Summary Feb 27 2015 - ZACKS

More From Other Websites
Company News for February 27, 2015 - Corporate Summary Feb 27 2015
Cowen Raises Price Targets on Top Momentum Stocks Feb 27 2015
Actavis' Infectious Disease Product, Avycaz, Gets FDA Nod - Analyst Blog Feb 26 2015
Amgen Reports Encouraging Late-Stage Data on AMG 416 - Analyst Blog Feb 26 2015
Medivation Beats on Q4 Earnings & Revenues; Xtandi Soars - Analyst Blog Feb 26 2015
Merge Healthcare (MRGE) Q4 Earnings Up Y/Y; Revenues Miss - Analyst Blog Feb 26 2015
BioMarin's Q4 Loss Narrower than Expected, Gives 2015 View - Analyst Blog Feb 26 2015
Orexigen (OREX) Misses Q4 Earnings, Contrave Impresses - Analyst Blog Feb 26 2015
Lightning Round: This group goes higher tomorrow Feb 25 2015
BioMarin Announces Fourth Quarter and Full Year 2014 Financial Results Feb 25 2015
BioMarin reports 4Q loss Feb 25 2015
BioMarin reports 4Q loss Feb 25 2015
Biomarin Pharmaceutical Inc Earnings Call scheduled for 4:30 pm ET today Feb 25 2015
BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 25 2015
BioMarin Announces Fourth Quarter and Full Year 2014 Financial Results Feb 25 2015
PTC Therapeutics for Sale? Only to a Foolish, Risk-Blind Buyer Feb 25 2015
Alkermes Falls on Pipeline News; Q4 Earnings Plunge Y/Y - Analyst Blog Feb 25 2015
Q4 2014 Biomarin Pharmaceutical Inc Earnings Release - After Market Close Feb 25 2015
Illumina Expands NGS Portfolio with NeoPrep Library System - Analyst Blog Feb 24 2015
Eli Lilly's BIL Filing Delayed, Baricitinib Scores in Phase III - Analyst Blog Feb 24 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK